Chemicals investments'
incentive and financing map.

Large-Scale Incentive is accessed when investments meet specific sector lists and minimum investment amounts. For strategic status, import dependency documentation and a higher investment amount threshold are also required. Petrochemical investments that can document import dependency are better suited to strategic status; raw material manufacturing investments generally qualify more readily for large-scale status.

Yes. Chemical process development, new synthesis routes and material R&D projects can benefit from grant support under TÜBİTAK 1501. If the project meets the scope of priority areas, programme 1511 offers higher grant rates. STB incentive certificate and TÜBİTAK support can run together; however, the same expenditure item cannot be submitted to both mechanisms.

Yes. Investments within Organised Industrial Zones are considered to be in the next higher region, so the incentive rate effectively increases by one region. This is particularly advantageous for investments in regions 3 and 4. The OIZ advantage must be taken into account in the investment site decision.

API (Active Pharmaceutical Ingredient) and fine chemicals manufacturers are assessed under both chemicals and pharmaceutical sector criteria. These companies can make use of the pharmaceutical sector's strategic investment incentive while also benefiting from large-scale incentive in the chemicals sector. The right classification must be established before application; choosing the wrong sector code may cause loss of significant advantages.

To establish an R&D centre under Law No. 5746, at least 15 full-time R&D personnel must be employed. In petrochemicals, this threshold is more feasible for companies with large engineering teams. R&D expenditures must be documented separately from production expenditures; the centre must operate in a physically separate space. The accreditation process takes 6 to 12 months on average.